The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Recent biotech deals are setting new valuation records for companies at specific early stages: preclinical (AbbVie/Capstan, ~$2B), Phase 1 (J&J/Halda, $3B), and pre-Phase 3 (Novartis/Abitivi, $12B). This signals intense demand for de-risked innovation well before late-stage data is available.

Servier's $2.5 billion acquisition of Day 1 Biopharmaceuticals is a strategic move to immediately gain a commercial oncology asset (Tovarofenib) and a related clinical pipeline. This highlights a common large pharma strategy of acquiring late-stage or already-marketed products to bypass early development risks and accelerate revenue growth.

To compete against entrenched pharma incumbents with massive market share, a new product cannot be merely similar. Mitzera attracted intense acquisition interest because its technology was fundamentally different, giving consumers and physicians a compelling reason to switch, which is the key concern for a potential acquirer's commercial team.

Merck cited Cedara's extensive, pre-Phase 3 research on pricing and cost-effectiveness as a key factor in its $10B acquisition. This demonstrates that early-stage biotechs can significantly increase their M&A value by proactively building a robust commercial case alongside their clinical development.

To achieve a 4% growth rate by 2031, large pharma firms need to acquire $69 billion in new sales. However, an analysis shows only 28 suitable public targets existed recently, and 10 have already been acquired in the last two years, creating a stark supply-demand imbalance for late-stage assets.

For years, Actuate's CEO has shared progress with large pharma companies, not just for early deal-making, but to get critical feedback on their development plan. This helps them understand what data potential acquirers need to see to make a compelling offer later.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.